Cargando…

Modification of Hemodialysis Membranes for Efficient Circulating Tumor Cell Capture for Cancer Therapy

Background: It is well known that more than 90% of cancer deaths are due to metastases. However, the entire tumorigenesis process is not fully understood, and it is evident that cells spreading from the primary tumor play a key role in initiating the metastatic process. Tumor proliferation and invas...

Descripción completa

Detalles Bibliográficos
Autores principales: Jarvas, Gabor, Szerenyi, Dora, Tovari, Jozsef, Takacs, Laszlo, Guttman, Andras
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8398911/
https://www.ncbi.nlm.nih.gov/pubmed/34443432
http://dx.doi.org/10.3390/molecules26164845
_version_ 1783744951441424384
author Jarvas, Gabor
Szerenyi, Dora
Tovari, Jozsef
Takacs, Laszlo
Guttman, Andras
author_facet Jarvas, Gabor
Szerenyi, Dora
Tovari, Jozsef
Takacs, Laszlo
Guttman, Andras
author_sort Jarvas, Gabor
collection PubMed
description Background: It is well known that more than 90% of cancer deaths are due to metastases. However, the entire tumorigenesis process is not fully understood, and it is evident that cells spreading from the primary tumor play a key role in initiating the metastatic process. Tumor proliferation and invasion also elevate the concentration of regular and irregular metabolites in the serum, which may alter the normal function of the entire human homeostasis and possibly causes cancer metabolism syndrome, also referred to as cachexia. Methods: We report on the modification of commercially available hemodialysis membranes to selectively capture circulating tumor cells from the blood stream by means of immobilized human anti-EpCAM antibodies on the inner surface of the fibers. All critical steps are described that required in situ addition of the immuno-affinity feature to hemodialyzer cartridges in order to capture EpCAM positive circulating tumor cells, which represents ~80% of cancer cell types. Results: The cell capture efficiency of the suggested technology was demonstrated by spiking HCT116 cancer cells both into buffer solution and whole blood and run through on the modified cartridge. Flow cytometry was used to quantitatively evaluate the cell clearance performance of the approach. Conclusions: The suggested modification has no significant effect on the porous structure of the hemodialysis membranes; it keeps its cytokine removal capability, addressing cachexia simultaneously with CTC removal.
format Online
Article
Text
id pubmed-8398911
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83989112021-08-29 Modification of Hemodialysis Membranes for Efficient Circulating Tumor Cell Capture for Cancer Therapy Jarvas, Gabor Szerenyi, Dora Tovari, Jozsef Takacs, Laszlo Guttman, Andras Molecules Article Background: It is well known that more than 90% of cancer deaths are due to metastases. However, the entire tumorigenesis process is not fully understood, and it is evident that cells spreading from the primary tumor play a key role in initiating the metastatic process. Tumor proliferation and invasion also elevate the concentration of regular and irregular metabolites in the serum, which may alter the normal function of the entire human homeostasis and possibly causes cancer metabolism syndrome, also referred to as cachexia. Methods: We report on the modification of commercially available hemodialysis membranes to selectively capture circulating tumor cells from the blood stream by means of immobilized human anti-EpCAM antibodies on the inner surface of the fibers. All critical steps are described that required in situ addition of the immuno-affinity feature to hemodialyzer cartridges in order to capture EpCAM positive circulating tumor cells, which represents ~80% of cancer cell types. Results: The cell capture efficiency of the suggested technology was demonstrated by spiking HCT116 cancer cells both into buffer solution and whole blood and run through on the modified cartridge. Flow cytometry was used to quantitatively evaluate the cell clearance performance of the approach. Conclusions: The suggested modification has no significant effect on the porous structure of the hemodialysis membranes; it keeps its cytokine removal capability, addressing cachexia simultaneously with CTC removal. MDPI 2021-08-10 /pmc/articles/PMC8398911/ /pubmed/34443432 http://dx.doi.org/10.3390/molecules26164845 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Jarvas, Gabor
Szerenyi, Dora
Tovari, Jozsef
Takacs, Laszlo
Guttman, Andras
Modification of Hemodialysis Membranes for Efficient Circulating Tumor Cell Capture for Cancer Therapy
title Modification of Hemodialysis Membranes for Efficient Circulating Tumor Cell Capture for Cancer Therapy
title_full Modification of Hemodialysis Membranes for Efficient Circulating Tumor Cell Capture for Cancer Therapy
title_fullStr Modification of Hemodialysis Membranes for Efficient Circulating Tumor Cell Capture for Cancer Therapy
title_full_unstemmed Modification of Hemodialysis Membranes for Efficient Circulating Tumor Cell Capture for Cancer Therapy
title_short Modification of Hemodialysis Membranes for Efficient Circulating Tumor Cell Capture for Cancer Therapy
title_sort modification of hemodialysis membranes for efficient circulating tumor cell capture for cancer therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8398911/
https://www.ncbi.nlm.nih.gov/pubmed/34443432
http://dx.doi.org/10.3390/molecules26164845
work_keys_str_mv AT jarvasgabor modificationofhemodialysismembranesforefficientcirculatingtumorcellcaptureforcancertherapy
AT szerenyidora modificationofhemodialysismembranesforefficientcirculatingtumorcellcaptureforcancertherapy
AT tovarijozsef modificationofhemodialysismembranesforefficientcirculatingtumorcellcaptureforcancertherapy
AT takacslaszlo modificationofhemodialysismembranesforefficientcirculatingtumorcellcaptureforcancertherapy
AT guttmanandras modificationofhemodialysismembranesforefficientcirculatingtumorcellcaptureforcancertherapy